Chris Viehbacher

Lilly And Sanofi CEOs Take Two Very Different R&D Paths In Alzheimer's Disease

Lilly And Sanofi CEOs Take Two Very Different R&D Paths In Alzheimer's Disease

Forbes

Dismay at Sanofi stance on Alzheimer's research

Dismay at Sanofi stance on Alzheimer's research

Pharma Times, UK

Sanofi Won’t Chase Alzheimer’s Therapies, Viehbacher Says

Sanofi Won’t Chase Alzheimer’s Therapies, Viehbacher Says

Bloomberg

Viehbacher Sees New Sanofi Growing in Diagnostics, Nutrition

Viehbacher Sees New Sanofi Growing in Diagnostics, Nutrition

Bloomberg

Sanofi's CEO On The New York Times' Criticism Of Drug Prices And Surviving The Patent Cliff

Sanofi's CEO On The New York Times' Criticism Of Drug Prices And Surviving The Patent Cliff

Forbes

Sanofi CEO Pledges ‘Thoughtful’ Job Cuts To Avoid Peugeot Drama

Sanofi CEO Pledges ‘Thoughtful’ Job Cuts To Avoid Peugeot Drama

Bloomberg

[video] Sanofi CEO's M&A Outlook

[video] Sanofi CEO's M&A Outlook

CNBC

Sanofi eyes 40 pct of sales from emerging mkts -CEO

Sanofi eyes 40 pct of sales from emerging mkts -CEO

Reuters

Sanofi CEO interested in emerging-market deals

Sanofi CEO interested in emerging-market deals

Reuters

Sanofi CEO Is Open to Deals of Up to $2.6 Billion This Year

Sanofi CEO Is Open to Deals of Up to $2.6 Billion This Year

Bloomberg